Investor Presentaiton
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Appendix
Innovation: Clinical trials
reinforcing our confidence in mid-term growth outlook
H1 sales
Cosentyx
USD 2.4 bn
+12%
Entresto
zolgensma®
KISQALI
USD 2.2 bn
USD 0.7 bn
USD 0.5 bn
+37%
+22%
+36%
References
Abbreviations
CE
K KL
Kesimpta
LEQVIO®
USD 0.4 bn
280%
nm
nm
Peak sales USD >7bn
US LOE 2029+
Peak sales USD >5bn
US LOE 2025-2036
Peak sales multi-bn¹
US LOE 2031+
Peak sales multi-bn
US LOE 2031+
Peak sales multi-bn
US LOE 2031+
nm not meaningful. All growth rates in constant currencies (cc). US LoEs are estimated based on relevant patents; further extensions possible. 1. Including Zolgensma® IT.
33 Investor Relations | Q2 2022 Results
Peak sales multi-bn
US LOE 2036+
U NOVARTIS | Reimagining MedicineView entire presentation